Article

Added RA relief with nighttime-release prednisone?

n an investigation of the effects of long-term low-dose chronotherapy with modified-release (MR) prednisone for rheumatoid arthritis (RA) on the hypothalamic-pituitary-adrenal (HPA) axis, treatment with nighttime-release prednisone did not change adrenocortical function over 12 months.

In an investigation of the effects of long-term low-dose chronotherapy with modified-release (MR) prednisone for rheumatoid arthritis (RA) on the hypothalamic-pituitary-adrenal (HPA) axis, treatment with nighttime-release prednisone did not change adrenocortical function over 12 months. Chronotherapy with this prednisone may improve the effectiveness of long-term low-dose corticosteroid treatment in patients with RA.

As part of the Circadian Administration of Prednisone in Rheumatoid Arthritis trial (CAPRA-1), Alten and colleagues explored the effects of chronotherapy with an MR nocturnally administered prednisone formulation that suppresses the morning cortisol surge. They performed corticotropin-releasing hormone (CRH) tests on 288 patients at baseline, during treatment with immediate-release (IR) prednisone; after 3 months on IR or MR prednisone; and after a 9-month open-label extension on MR prednisone.

Treatment with MR prednisone for 12 months did not change the CRH test results. Cortisol levels were unchanged from baseline (IR prednisone) to end of study (MR prednisone). Thus, there was no new HPA axis suppression. Patients taking MR prednisone for up to 12 months remained free of adverse effects.

The authors proposed that treatment with MR prednisone can offer an extra dose of medication when it is most needed, thereby potentially providing additional control of RA.

Related Videos
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.